Volker Heinemann
0000-0002-1349-3321
Publication & Citation Trends
Publications
0 total
6MO Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1
Cited by 1
Semantic Scholar
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO.
Cited by 3
Semantic Scholar
2247P Growth differentiation factor 15 (GDF-15) in localized, non-metastatic pancreatic cancer treated with multiagent induction chemotherapy: A biomarker analysis from the randomized phase II NEOLAP-1 trial (AIO-PAK-0113)
Cited by 0
Semantic Scholar
2221P Final results of FOOTPATH: A randomized, open-label phase-II study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC)
Cited by 0
Semantic Scholar
745P Estimating the clinical benefit of the secondary resection of metastases in liver-limited metastatic colorectal cancer: An individual patient data-based pooled analysis of nine randomized trials
Cited by 0
Semantic Scholar
825P Chronological changes in clinical outcomes of standard first-line oxaliplatin-based chemotherapy + targeted agents for metastatic colorectal cancer: Updated analysis of the ARCAD database
Cited by 0
Semantic Scholar
407P Immune composition-based efficacy assessment of first-line immune-chemotherapy combinations in gastroesophageal cancer: Subgroup analysis of the phase II IKF-AIO-STO-0417 / moonlight trial
Cited by 0
Semantic Scholar
LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial
Cited by 5
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(565)
Pancreatic and Hepatic Oncology Research
(260)
Cancer Genomics and Diagnostics
(237)
Lung Cancer Treatments and Mutations
(204)
Gastric Cancer Management and Outcomes
(167)
Affiliations
Roche (Switzerland)
Novartis (Switzerland)
Amgen (United States)
The University of Texas MD Anderson Cancer Center
Witten/Herdecke University